文献速递核素与放射性配体治疗放射性药物与辐射防护

177Lu-PSMA-617放射配体治疗在转移性去势抵抗性前列腺癌中的血液学安全性

Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.
PubMed 文献 · EJNMMI Res · 2021-07-03

该研究纳入140例接受497个周期177Lu-PSMA-617治疗的mCRPC患者,评估血液学不良事件的发生、严重程度及可逆性。3级及以上血液学不良事件发生率为9.3%,多数可逆;既往2级血细胞减少、高骨肿瘤负荷及紫杉烷类化疗史为危险因素,而累积治疗活度和既往223Ra治疗无显著贡献。

要点

  • 3级及以上血液学不良事件发生率9.3%,以贫血、白细胞减少和血小板减少为主。
  • 除2例早期死亡外,血液学毒性中位随访8个月均逆转为≤2级。
  • 既往2级血细胞减少、高骨肿瘤负荷、紫杉烷化疗史增加骨髓抑制风险。

核心结论

  • 177Lu-PSMA-617放射配体治疗的血液学不良事件总体发生率可接受且常可逆。
  • 高骨肿瘤负荷、既往紫杉烷类化疗和治前2级血细胞减少可能是临床相关骨髓抑制的危险因素。
  • 累积RLT活度和既往223Ra-dichloride治疗对血液学毒性发生率无显著贡献。

研究设计与样本

  • 单中心研究纳入140例mCRPC患者,共接受497个周期177Lu-PSMA-617治疗。
  • 每周期平均活度6.9±1.3 GBq,平均累积活度24.6±15.9 GBq。
  • 基线和每周期前后及随访期监测血液学参数,按CTCAE v5.0分级。

主要发现

  • 13例(9.3%)患者发生≥3级血液学不良事件,其中贫血10例(7.1%)、白细胞减少5例(3.6%)、血小板减少6例(4.3%)。
  • 中位随访8个月(IQR 9),除2例在RLT后3个月内死于疾病进展外,血液毒性均逆转为≤2级。
  • 治前2级血细胞减少者骨髓抑制风险显著增高(OR 3.50,95%CI 1.08-11.32,p=0.04)。
  • 高骨肿瘤负荷(PROMISE miTNM弥漫或播散型)者风险显著增高(OR 5.08,95%CI 1.08-23.86,p=0.04)。
  • 既往紫杉烷类化疗与显著血液毒性发生率增加相关(OR 4.62,95%CI 1.23-17.28,p=0.02)。

关键数值与推荐

  • ≥3级血液学不良事件:贫血7.1%、白细胞减少3.6%、血小板减少4.3%。
  • 治前2级血细胞减少:OR 3.50(95%CI 1.08-11.32,p=0.04)。
  • 高骨肿瘤负荷:OR 5.08(95%CI 1.08-23.86,p=0.04)。
  • 既往紫杉烷类化疗:OR 4.62(95%CI 1.23-17.28,p=0.02)。
  • 既往223Ra治疗、累积活度、每周期活度与血液毒性无显著相关(p=0.93、0.33、0.29)。

临床怎么用

  • 治疗前应评估血细胞计数和骨肿瘤负荷,识别骨髓抑制高危患者。
  • 对既往紫杉烷化疗或治前2级血细胞减少者加强血液学监测。
  • 血液学毒性多为可逆,支持在密切监测下继续治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myelosuppression is a potential dose-limiting factor in radioligand therapy (RLT). This study aims to investigate occurrence, severity and reversibility of hematotoxic adverse events in patients undergoing RLT with 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC). The contribution of pretreatment risk factors and cumulative treatment activity is taken into account specifically. METHODS: RLT was performed in 140 patients receiving a total of 497 cycles. A mean activity of 6.9 [Formula: see text] 1.3 GBq 177Lu-PSMA-617 per cycle was administered, and mean cumulative activity was 24.6 [Formula: see text] 15.9 GBq. Hematological parameters were measured at baseline, prior to each treatment course, 2 to 4 weeks thereafter and throughout follow-up. Toxicity was graded based on Common Terminology Criteria for Adverse Events v5.0. RESULTS: Significant (grade ≥ 3) hematologic adverse events occurred in 13 (9.3%) patients, with anemia in 10 (7.1%), leukopenia in 5 (3.6%) and thrombocytopenia in 6 (4.3%). Hematotoxicity was reversible to grade ≤ 2 through a median follow-up of 8 (IQR 9) months in all but two patients who died from disease progression within less than 3 months after RLT. Myelosuppression was significantly more frequent in patients with pre-existing grade 2 cytopenia (OR: 3.50, 95%CI 1.08-11.32, p = 0.04) or high bone tumor burden (disseminated or diffuse based on PROMISE miTNM, OR: 5.08, 95%CI 1.08-23.86, p = 0.04). Previous taxane-based chemotherapy was associated with an increased incidence of significant hematotoxicity (OR: 4.62, 95%CI 1.23-17.28, p = 0.02), while treatment with 223Ra-dichloride, cumulative RLT treatment activity and activity per cycle were not significantly correlated (p = 0.93, 0.33, 0.29). CONCLUSION: Hematologic adverse events after RLT have an acceptable overall incidence and are frequently reversible. High bone tumor burden, previous taxane-based chemotherapy and pretreatment grade 2 cytopenia may be considered as risk factors for developing clinically relevant myelosuppression, whereas cumulative RLT activity and previous 223Ra-dichloride treatment show no significant contribution to incidence rates.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Groener D, Nguyen CT, Baumgarten J, et al. Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. EJNMMI Res. 2021. PMID: 34216290. doi:10.1186/s13550-021-00805-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。